



Cell Signaling in Cancer and Cancer Therapy

Guest Editors:

Prof. Dr. Zhixiang Wang

Signal Transduction Research
Group, Department of Medical
Genetics, Faculty of Medicine and
Dentistry, University of Alberta,
Edmonton, AB T6G 2H7, Canada

Dr. Yi Wang

1. Canadian Nuclear
Laboratories, Chalk River, ON,
Canada
2. Department of Biochemistry,
Microbiology and Immunology,
Faculty of Medicine, University of
Ottawa, Ottawa, ON, Canada

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

One hallmark of cancer is the aberrant cell signaling which is caused by the dysregulation of signaling proteins. Hyperactivation or dysregulation of these signaling pathways can result in transformation of cellular proto-oncogenes to oncogenes. On the other hand, the inactivation of tumor suppressors eliminates important negative regulators of signaling, which results in uncontrolled cell proliferation and subsequent tumor development. The knowledge of cellular signal transduction pathways will be essential to understand the evolution of a pathological condition and the delicate balance that regulates cellular homeostasis.

Recently, targeting the component of cell signaling in cancer has emerged as the most prominent aspect of cancer treatment. In this Special Issue, we invite all papers that study the cell signaling underlying any aspects of cancer development. Research on the signaling pathway behind cancer therapies including targeted, immune, radiation and chemo-therapy are also welcomed. This Special Issue invites both original research articles as well as reviews, commentaries, and perspectives that cover all aspects of signal transduction.





cancers



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (*Oncology*) / CiteScore - Q1 (*Oncology*)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
X@Cancers_MDPI